– Recently initiated a pre-clinical trial with CollPlant’s rhCollagen-based regenerative breast implants, printed with Stratasys’ Origin ® 3D printer that are 200cc in volume
– Breast implants could address a $3.0 billion market opportunity
– Cash and cash equivalents balance as of June 30, 2024 was $18.9 million – Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ — CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial […]
Full Post at www.prnewswire.com